Equity · Healthcare
ALKS
NASDAQAlkermes (ALKS)
The line runs 49 USD on 10 August through 45.92 USD on 6 November, on a scale from 35 to 55. Days the market did not trade hold the previous close, flat.
- Market cap
- 7.7B USD
- Revenue, year to Dec 2025
- 1.5B USD
- EPS, diluted, year to Dec 2025
- 1.43 USD
- 52-week range
- 27.21 USD – 55 USD
- Avg volume
- 130.0K
as of Nov 6, 2026
Have Alkermes (ALKS) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Alkermes insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 3 Nov 2025, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 3 Nov 2026
Buys 0Sells 5Net sold $1.07MOther filings 3
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 03 Nov 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sell | 2,035 | 94K USD |
| 02 Oct 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sell | 2,034 | 83K USD |
| 03 Sep 2026 | Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sell | 2,034 | 98K USD |
| 01 Sep 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sell | 9,000 | 423K USD |
| 17 Aug 2026 | Nichols Christian ToddSVP, Chief Commercial Officer | Sell | 7,576 | 373K USD |
| Sold | 5 open-market sales | 22,679 | $1.07M |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 08 Oct 2026 | Reed JoshuaSVP, Chief Financial Officer | Option exercise | 9,164 | |
| 08 Oct 2026 | Reed JoshuaSVP, Chief Financial Officer | Tax withheld | 4,069 | 163K USD |
| 01 Sep 2026 | Hopkinson Craig C.EVP R&D, Chief Medical Officer | Option exercise | 5,000 | 123K USD |
Which funds hold Alkermes (ALKS)?
1 of the 45 institutional funds we track reported a Alkermes position for the quarter ended 30 Sep 2026 — a combined 17.6M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 433,263 | 17.6M USD | +3.4% |
Have members of Congress traded Alkermes (ALKS)?
The most recent congressional trade disclosed in Alkermes is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 29 Sep 2026.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 29 Sep 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 13 days |
| 30 Jul 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 15K USD–50K USD | 36 days |
What has been filed or recorded for Alkermes (ALKS)?
The filings we hold for Alkermes, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 445 shares | 18K USD notional · <0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 5 shares | 201 USD notional · <0.001% of shares out |
| 06 Oct 2026 | Fails to deliver | Shares failed to deliver | 5,666 shares | 242K USD notional · 0.003% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.09 USD | Revenue $480M |
| 30 Sep 2026 | Financials | Total assets | 4.4B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 1.9B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.00 USD | Revenue $496M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.40 USD | Revenue $393M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 1.43 USD | Revenue $1.48B |
| 31 Dec 2025 | Financials | Revenue | 1.5B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 241.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 1.43 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.49 USD | Revenue $394M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.52 USD | Revenue $391M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.13 USD | Revenue $307M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 2.17 USD | Revenue $1.56B |
Alkermes (ALKS): frequently asked questions
What did Alkermes shares close at?
Alkermes closed at 45.92 USD on 6 Nov 2026, up 4.36% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Alkermes’ market cap?
Alkermes is worth 7.7B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Alkermes’ revenue?
Alkermes reported revenue of 1.5B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Alkermes insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Alkermes insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 3 Nov 2025, show no open-market purchase. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Alkermes?
1 of the 45 funds we track reported a Alkermes position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Have members of Congress traded Alkermes?
Yes. 2 trades in Alkermes appear in the congressional disclosures we hold; the latest is a purchase by Gilbert Ray Cisneros, Jr. (House, CA) dated 29 Sep 2026, filed 12 Oct 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Alkermes last report earnings?
Alkermes last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.09 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- Wikipediatext of the lead paragraph, licensed CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) — https://en.wikipedia.org/wiki/Alkermes_plc